Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.

Gail M GauvreauJens M HohlfeldJ Mark FitzGeraldLouis-Philippe BouletDonald W CockcroftBeth E DavisStephanie KornOliver KornmannRichard LeighIrvin MayersHenrik WatzSarah S GrantMonish JainMaciej CabanskiPeter E PertelIeuan JonesJean R LecotHui CaoPaul M O'Byrne

Published in: The European respiratory journal (2023)

Ecleralimab significantly attenuated allergen-induced bronchoconstriction and airway inflammation, and was safe in subjects with mild atopic asthma.

Keyphrases

allergic rhinitis
chronic obstructive pulmonary disease
lung function
cystic fibrosis
high glucose
diabetic rats
drug induced
air pollution
oxidative stress